Free shipping on orders over $500 throughout NSW and to all interstate Capitals.
Currency
Toggle Nav
Chronic Myeloid Leukemia
Regular Price
$175.00
Special Price
$157.50
$143.18
Stock Status:
1-2 days delivery
Availability:
In stock
SKU
9780849379550
Chronic Myeloid Leukemia (CML) remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level and has been used by researchers to develop a variety of therapies and therapeutic assessment methods. This concise, readable guide assembles and synthesizes the latest developments and trends in the treatment of CML and provides an authoritative and convenient summary of the latest progress in imatinib trials, the molecular monitoring of CML responses, and the engineering of new therapies to overcome resistance and improve patient care.
Providing critical insight and exploration of models that will enhance the cancer community at large, this source:
- stands as the only source to focus on post-Gleevec developments in CML therapeutics
- collects information from the forefront of the field—helping busy clinicians make informed management decisions
- supplies critical research from recognized opinion leaders on the topic
- provides an overview of the current status of new transplant modalities
- contains a vivid selection of color photographs
| Author | Jorge Cortes, Michael Deininger |
|---|---|
| Table Of Content | BCR-ABL as a Molecular Target. Long-Term Results of Stem Cell Transplant. Where are We Today with Imatinib Therapy. Monitoring CML in 2006. Monitoring CML in 2006. Dasatinib: a Dual Abl and Src Inhibitor. AMN107. Resistance to Imatinib. Immunotherapy. Non-Immunological, non TKI Targets. Non-Immunological, non TKI Targets. CML in Transformation. Early Intensification of Therapy |
| Publish Date | 30 Jun 2010 |
Write Your Own Review